Efficacy and Safety of Amlodipine Camsylate(Amodipin(TM)) for Treatment of Essential Hypertension

Abstract

Background and Objectives:Amlodipine camsylate (Amodipin), a newly developed amlodipine formulation, has similar physical properties and pharmacokinetic equivalency to that of the conventional formulation (amlodipine besylate, Norvasc®). Subjects and Methods:This prospective, randomized, double-blind, parallel designed, multicenter study was conducted at a total of 7 sites. 95 patients with mild to moderate essential hypertension were enrolled. Following the 2 week administration of a placebo, the patients received 5 mg of amlodipine once a day for a total of 8 weeks. If either the blood pressure was ≥140/90 mmHg or the sitting diastolic blood pressure had not decreased by ≥10 mmHg from those at the baseline after 4 weeks of treatment, the dose of amlodipine was increased to 10 mg. The blood pressure was measured twice every 4 weeks and mean value recorded. Results:The diastolic and systolic blood pressures were significantly decreased with both amlodipine camsylate (baseline DBP: 97.4±5.8 mmHg, 8 th week DBP: 84.1±8.8 mmHg, mean differences: -13.3±7.4) and amlodipine besylate (baseline DBP: 95.9±5.9 mmHg, 8 th week DBP: 83.2±9.2 mmHg, mean differences: -12.4±8.3). The incidence of drug related adverse events was similar in both groups. Conclusion: This study suggests that once-a-day monotherapy of amlodipine camsylate is effective for the control of blood pressure in patients with essential hypertension, without significant adverse events. (Korean Circulation J 2005;35:247-252)